Drugs / Arginine Butyrate
Arginine Butyrate
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00006340 | Dec 1994 → Jul 2000 | leukemia, lymphoma, precancerous condition, small intestine cancer | Boston Medical Center | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00992732 | May → Nov 2010 | lymphoid neoplasm, lymphoproliferative syndrome | HemaQuest Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00917826 | Sep 2008 → Sep 2009 | lymphoma, lymphoproliferative syndrome | HemaQuest Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00006136 | Mar 1999 → ? | beta-thalassemia intermedia | Boston University | Completed | No outcome recorded |
| Phase 2 | NCT00004412 | Sep 1997 → Dec 2002 | sickle cell disease, ulcer of lower limbs | Susan P. Perrine | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | arginine butyrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006340 ↗ |
| Known as | Arginine butanoate | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067996 ↗ |
| Known as | HQK-1004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00992732 ↗ |
| Known as | L-arginine, butanoate (3:4) | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067996 ↗ |
| Known as | Vx 105 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067996 ↗ |
| Action | Activate | “arginine butyrate was not only effective in inducing EBV thymidine kinase transcription” PMID 9628848 ↗ Jun 1998 |
| Modality | Small molecule | — CHEMBL6067996 ↗ |
| Route | Intravenous | “Arginine butyrate IV over 6-9 hours at night 5 days a week for 12 weeks” NCT00004412 ↗ |